Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 6/20 | 0.35 |
| ▸ | RET | P07949 | 5/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210958 | 0.90 | RET (0.34) | BUB1RETCACNA1HPDE10ASCN9A | |
| SCHEMBL29907180 | 0.89 | BUB1 (0.37) | BUB1RETCACNA1HGRIN2B | |
| SCHEMBL23210866 | 0.89 | BUB1 (0.37) | BUB1RETCACNA1HGRIN2B | |
| SCHEMBL23211100 | 0.87 | RET (0.35) | BUB1RETCACNA1HGRIN2B | |
| SCHEMBL29008859 | 0.85 | BUB1 (0.37) | BUB1RETCACNA1HGRIN2B | |
| SCHEMBL29907095 | 0.84 | AAK1 (0.37) | BUB1RETCACNA1HPDE10AGRIN2B | |
| SCHEMBL23263997 | 0.84 | AAK1 (0.37) | BUB1RETCACNA1HPDE10AGRIN2B | |
| SCHEMBL29907070 | 0.80 | BUB1 (0.42) | BUB1PDE10AGRIN2B | |
| SCHEMBL23210943 | 0.80 | BUB1 (0.42) | BUB1PDE10AGRIN2B | |
| SCHEMBL23210675 | 0.79 | RET (0.36) | BUB1RETCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | BUB1 412/4885RET 24/4885PDCD1 488/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | BUB1 412/4885RET 24/4885PDCD1 488/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | BUB1 412/4885RET 24/4885PDCD1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.